Loading organizations...
§ Private Profile · 901 Mariners Island Blvd, Suite 700, San Mateo, CA, 94404
Biotech company developing AI-powered blood tests for early and accurate chronic disease detection, using Whole-Body Intelligence.
Curve Biosciences is a Dallas, Texas-based biotechnology company that develops artificial intelligence-powered blood tests for the early detection and monitoring of chronic diseases. The organization utilizes its proprietary Whole-Body Atlas, a molecular blueprint constructed from an extensive curated collection of human tissue samples, to provide physicians with precise diagnostic intelligence for patient care. Initially operating out of San Mateo, California, the enterprise relocated its corporate headquarters to the Pegasus Park development in Texas to scale its clinical operations. The firm has raised $40 million in total venture funding, with its most recent investment capital led by Luma Group. Operating as a spin-out from Stanford University, the company recruited an executive leadership team featuring former scientists from prominent diagnostics companies including GRAIL, Natera, and Counsyl. Curve Biosciences was founded in 2023 by Ritish Patnaik and Professor Shan Wang.
Curve Biosciences has raised $40.0M across 1 funding round.
Curve Biosciences has raised $40.0M in total across 1 funding round.
Curve Biosciences has raised $40.0M in total across 1 funding round.
Curve Biosciences's investors include Luma Group, Micah Spear, Civilization Ventures, First Spark Ventures, LifeX Ventures, Techas Capital.
Curve Biosciences has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series A in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2025 | $40M Series A | Luma Group | Micah Spear, Civilization Ventures, First Spark Ventures, LifeX Ventures, Techas Capital | Announced |
Curve Biosciences is a precision medicine biotech company developing Whole-Body Blood Tests powered by AI models trained on the Whole-Body Atlas, the world's largest manually curated collection of comprehensively characterized human tissue samples.[1][2][3][4] It serves doctors, patients with chronic diseases, insurers, and pharma companies by solving the problem of inaccurate, expensive, and late-stage monitoring through earlier, more accurate detection of disease states via simple blood tests anchored in tissue-level biological data.[1][3][4] The company has raised approximately $57.69M in total funding, including a $40M round in 2024 led by Luma Group to advance clinical validation, commercialization, and its new Dallas headquarters at Pegasus Park, with reported revenue between $1M-$10M and strong growth momentum from California origins to Texas expansion.[2][3]
Curve Biosciences was founded in 2021 by Ritish Patnaik (CEO, from Plano, Texas; Columbia undergrad, Stanford PhD), Chuba Oyolu, and Nathan Hunkapiller (PhD, ex-Stanford Wang Group alum named chief something in recent spotlight).[2][3][6] Patnaik launched the company several years ago from San Mateo, California, after pursuing advanced biotech research, driven by the need to create a molecular blueprint of the human body from tissue data to improve chronic disease monitoring beyond opaque blood-based models.[1][3][4] Early traction included a $17.69M venture round in May 2024 led by Life Extension Ventures and NZVC, followed by the pivotal $40M raise enabling HQ relocation to Dallas' Pegasus Park biotech hub, marking a return to Patnaik's Texas roots while retaining California operations.[2][3]
Curve rides the AI-driven precision medicine wave in biotech, targeting chronic disease monitoring—a market strained by ineffective tools amid aging populations and rising disease burdens.[1][3][5] Timing is ideal post-2024 funding boom, aligning with advances in multi-omics data and tissue-anchored AI, as investors bet on "next frontier" clinical testing with reimbursement paths.[3] Favorable forces include biotech hubs like Pegasus Park fostering innovation, demand for proactive diagnostics over reactive care, and convergence of health diagnostics, AI, and personalized treatments.[2][3] Curve influences the ecosystem by pioneering whole-body molecular mapping, potentially reshaping how pharma develops drugs and insurers manage costs through data-driven outcomes.[1][3]
Curve is poised to launch detailed platform info and chronic disease pipeline updates soon, accelerating commercialization of blood tests with $40M fueling clinical trials and Dallas scaling.[3] Trends like AI-tissue integration and value-based care will propel growth, evolving Curve from startup to ecosystem leader in transforming chronic disease management from reactive to predictive. As the first to blueprint the body at scale, it anchors biotech's shift to biological truth, promising alleviated patient pain and optimized medicine.[1][3]